Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yuji Takeyama"'
Autor:
Shoma Yamamoto, Minoru Kato, Yuji Takeyama, Yukari Azuma, Nao Yukimatsu, Yukiyoshi Hirayama, Taiyo Otoshi, Takeshi Yamasaki, Masaki Fujioka, Min Gi, Hideki Wanibuchi, Junji Uchida
Publikováno v:
British Journal of Cancer.
Background Radiotherapy (RT) has recently been highlighted as a partner of immune checkpoint inhibitors. The advantages of RT include activation of lymphocytes while it potentially recruits immunosuppressive cells, such as myeloid-derived suppressor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63d216ca6e08af66cb380177cb603dc2
https://doi.org/10.1038/s41416-023-02244-8
https://doi.org/10.1038/s41416-023-02244-8
Autor:
Minoru Kato, Taro Iguchi, Satoshi Tamada, Yuji Takeyama, Yukari Azuma, Yasuomi Shimizu, Tatsuya Nakatani, Hideki Wanibuchi, Min Gi, Takeshi Yamasaki
Publikováno v:
Cancer Letters. 479:89-99
Myeloid-derived suppressor cells (MDSCs) are one of the key players that contribute to immune evasion. The purpose of the present study was to investigate whether MDSCs could be a novel target for the treatment of cisplatin-resistant bladder cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94cddbae1eda17d7d6474e8dfcf48d7
https://doi.org/10.1016/j.canlet.2020.03.013
https://doi.org/10.1016/j.canlet.2020.03.013
Autor:
Minoru Kato, Katsuyuki Kuratsukuri, Shoma Yamamoto, Yukiyoshi Hirayama, Junji Uchida, Takeshi Yamasaki, Yuji Takeyama, Nao Yukimatsu, Taiyo Otoshi
Publikováno v:
Urologic oncology. 40(5)
Background Recently, switch maintenance with avelumab has been approved for the treatment of advanced or metastatic urothelial carcinoma (UC), with no progression after four to six cycles of first-line platinum-based chemotherapy. However, the optima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de17015c5fc733f103fe43f5b633d44
https://pubmed.ncbi.nlm.nih.gov/34852939
https://pubmed.ncbi.nlm.nih.gov/34852939
Autor:
Anna Kakehashi, Minoru Kato, Satoshi Tamada, Yuji Takeyama, Tatsuya Nakatani, Min Gi, Masaki Fujioka, Yasuomi Shimizu, Hideki Wanibuchi
Publikováno v:
Experimental and Therapeutic Medicine
Androgen signal has been recently suggested to be associated with the progression of bladder cancer. Steroid sulfatase (STS) is a steroid sulfate activation enzyme, considered to be one of the key enzymes in the androgen signaling pathway. However, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c804e5177b9486578230374c81292635
http://europepmc.org/articles/PMC6257456
http://europepmc.org/articles/PMC6257456
Autor:
Takeshi Yamasaki, Satoshi Tamada, Tatsuya Nakatani, Katsuyuki Kuratsukuri, Minoru Kato, Yuji Takeyama, Taro Iguchi, Chikako Nishihara
Publikováno v:
International Journal of Clinical Oncology. 23:944-950
The aim of this study was to evaluate the efficacy and toxicities of second-line chemotherapy regimens with docetaxel and gemcitabine (GD), or paclitaxel and gemcitabine (GP) for advanced or metastatic urothelial carcinoma (UC) that did not respond t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46853bc7f9fdae368f5c95b67757f7f3
https://doi.org/10.1007/s10147-018-1288-1
https://doi.org/10.1007/s10147-018-1288-1
Autor:
Yuji Takeyama, Minoru Kato, Sayaka Yasuda, Taro Iguchi, Tatsuya Nakatani, Yasuomi Shimizu, Satoshi Tamada, Takeshi Yamasaki
Publikováno v:
Journal of Urology. 197
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e6a5a608ade242c16e3b109c0bd7bfe
https://doi.org/10.1016/j.juro.2017.02.1780
https://doi.org/10.1016/j.juro.2017.02.1780
Autor:
Minoru Kato, Tatsuya Nakatani, Yasuomi Shimizu, Taro Iguchi, Satoshi Tamada, Yuji Takeyama, Kosuke Hamada
Publikováno v:
Journal of Clinical Oncology. 37:415-415
415 Background: The emergence of immune checkpoint inhibitors (ICI) has brought hope for cure and survival for those suffering from various cancers, including bladder cancer. However, the response rate of ICI monotherapy is modest, and recent reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07b4a483bac34b4dac94f5e6fced0262
https://doi.org/10.1200/jco.2019.37.7_suppl.415
https://doi.org/10.1200/jco.2019.37.7_suppl.415
Autor:
Sayaka Yasuda, Satoshi Tamada, Taro Iguchi, Takeshi Yamasaki, Yuji Takeyama, Tatsuya Nakatani, Minoru Kato, Yasuomi Shimizu, Kosuke Hamada
Publikováno v:
Journal of Clinical Oncology. 37:293-293
293 Background: In Asia, including Japan, combined androgen blockade (CAB) therapy with bicalutamide is widely used for metastatic prostate cancer. Alternative anti-androgen therapy (AAT) with flutamide (FLU) after CAB therapy with bicalutamide was c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca91431139cebdffef1c9ecf4ba0e578
https://doi.org/10.1200/jco.2019.37.7_suppl.293
https://doi.org/10.1200/jco.2019.37.7_suppl.293
Autor:
Yasuomi Shimizu, Satoshi Tamada, Kosuke Hamada, Taro Iguchi, Tatsuya Nakatani, Minoru Kato, Yuji Takeyama
Publikováno v:
Journal of Clinical Oncology. 37:302-302
302 Background: Expression of androgen receptor (AR) splice variant 7 (AR-V7) has been identified as a mechanism associated with the development of castration-resistant prostate cancer (CRPC), but a potential link between AR-V7 expression and resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed2927af8167b1b487c1ac2a0deb18cb
https://doi.org/10.1200/jco.2019.37.7_suppl.302
https://doi.org/10.1200/jco.2019.37.7_suppl.302